ClinicalTrials.gov
public full text
Public Domain
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
bladder-cancercholangiocarcinomacolorectal-cancergastric-cancerhepatocellular-carcinomahnsccmelanomamerkel-cell-carcinoma
Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. The investigators anticipate that the results of this study will answer questions regarding the optimal duration of treatment. therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors#1171778
- Lamivudine for Solid Tumors#843376
- Study of INCB086550 in Select Solid Tumors#1030713
- Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma#1281589
- A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors#346918
Record · ID 1375622
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive